Janssen Submits Biologics License Application to U.S. FDA Seeking Approval of Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

By In The News
December 29, 2021 in The Headlines

Followers 0

Recommended Posts

In The News

Posted December 29, 2021

- Share

Posted December 29, 2021

RARITAN, N.J., Dec. 29, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of teclistamab for the treatment of patients with...

View the full article

Link to comment

Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign in

Already have an account? Sign in here.

Followers 0

Go to topic listing

Most Contributions
1. In The News
  221112
2. Jaydee
  17346
3. deicer
  12756
4. Kip Powick
  12274
5. dagger
  9601
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  271.5k
- Total Posts
  
  562.1k

Sign In

Janssen Submits Biologics License Application to U.S. FDA Seeking Approval of Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Recommended Posts

In The News

Link to comment

Share on other sites

Create an account or sign in to comment

Create an account

Sign in

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support